These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23122665)

  • 21. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
    J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dilemmas of prostate cancer screening.
    Del Mar CB
    Med J Aust; 2013 Nov; 199(9):584. PubMed ID: 24182218
    [No Abstract]   [Full Text] [Related]  

  • 24. The dilemmas of prostate cancer screening.
    Hugosson J; Carlsson SV
    Med J Aust; 2013 Nov; 199(9):583-4. PubMed ID: 24182217
    [No Abstract]   [Full Text] [Related]  

  • 25. The dilemmas of prostate cancer screening.
    Lawrentschuk N; Murphy DG; Costello AJ
    Med J Aust; 2013 Nov; 199(9):583. PubMed ID: 24182216
    [No Abstract]   [Full Text] [Related]  

  • 26. The dilemmas of prostate cancer screening.
    Haines IE
    Med J Aust; 2013 Nov; 199(9):582-3. PubMed ID: 24182215
    [No Abstract]   [Full Text] [Related]  

  • 27. The dilemmas of prostate cancer screening.
    McKenzie PR; Delahunt B; Kench JG
    Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182214
    [No Abstract]   [Full Text] [Related]  

  • 28. The dilemmas of prostate cancer screening.
    Miklos GG
    Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182213
    [No Abstract]   [Full Text] [Related]  

  • 29. Active surveillance for favorable risk prostate cancer.
    Carter HB
    Curr Opin Urol; 2015 May; 25(3):230-1. PubMed ID: 25730328
    [No Abstract]   [Full Text] [Related]  

  • 30. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
    Luján M; Páez Á
    Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
    [No Abstract]   [Full Text] [Related]  

  • 31. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Active surveillance of low risk prostate cancer].
    Weißbach L
    Urologe A; 2015 Jun; 54(6):869-70. PubMed ID: 26081819
    [No Abstract]   [Full Text] [Related]  

  • 33. Screening and active surveillance in prostate cancer: the dilemma continues.
    Hamdy FC; Albertsen PC; Donovan JL
    BJU Int; 2024 Jul; 134(1):1-2. PubMed ID: 38514989
    [No Abstract]   [Full Text] [Related]  

  • 34. Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    Tosoian JJ; Carter HB
    J Urol; 2017 Nov; 198(5):997-999. PubMed ID: 28947084
    [No Abstract]   [Full Text] [Related]  

  • 35. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    McKenzie PR; Delahunt B; Kench JG; Sikaris KA
    Pathology; 2014 Jan; 46(1):91-2. PubMed ID: 24300730
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
    Zardawi IM
    Pathology; 2014 Jan; 46(1):91. PubMed ID: 24300722
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostate cancer - active surveillance as a management option.
    Yaxley J; Yaxley J; Gardiner R; Yaxley W
    Aust Fam Physician; 2013; 42(1-2):74-6. PubMed ID: 23529468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?
    Al Edwan G; Fleshner N
    Curr Urol Rep; 2013 Jun; 14(3):223-6. PubMed ID: 23579402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 40. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection?
    Edmund L; Rotker KL; Lakis NS; Brito JM; Lepe M; Lombardo KA; Renzulli JF; Matoso A
    Hum Pathol; 2017 Jan; 59():87-93. PubMed ID: 27720731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.